Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2020

01-12-2020 | Itraconazole | Research article

Application of the adenosine triphosphate sensitivity assay in infantile vascular anomalies

Authors: Li Li, Bin Yang, Li Wei, Bin Zhang, Xiao-feng Han, Zi-gang Xu, Lin Ma

Published in: BMC Pediatrics | Issue 1/2020

Login to get access

Abstract

Background

The term vascular anomalies include various vascular tumors and vascular malformations, among them infantile hemangiomas and capillary malformations are the most well-known associated diseases in early ages. Multiple drugs have been introduced for intervention, but susceptibility test in vitro were scarcely reported.

Objective

To evaluate the inhibition effect of different drugs by adenosine triphosphate sensitivity assay in vitro before the treatment of infantile hemangiomas and capillary malformations.

Methods

Specimens were selected from 5 cases of infantile hemangiomas and 11 cases of capillary malformations. Propranolol, rapamycin, sildenafil and itraconazole were tested for their growth inhibition effect by using the adenosine triphosphate sensitivity assay.

Results

Propranolol demonstrated inhibitory effects on infantile hemangiomas cells. Rapamycin and itraconazole both showed inhibitory effects on infantile hemangiomas cells and capillary malformations cells. Sildenafil has no growth inhibitory effect on infantile hemangiomas cells or capillary malformations cells.

Conclusion

Adenosine triphosphate sensitivity assay is a sensitive and useful testing method before the management of vascular anomalies, and individualized medication suggestions for the choice of therapeutic drugs were offered based on the testing result and together with a comprehensive evaluation of each infant.
Literature
1.
2.
Sadick M, Müller-Wille R, Wildgruber M, Wohlgemuth WA. Vascular anomalies (part I): classification and diagnostics of vascular anomalies. Rofo. 2018;190(9):825–35.PubMedCrossRef
3.
Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168–73.PubMedCrossRef
4.
5.
McCuaig CC. Update on classification and diagnosis of vascular malformations. Curr Opin Pediatr. 2017;29(4):448–54.PubMedCrossRef
6.
Chinnadurai S, Sathe NA, Surawicz T. Laser treatment of infantile hemangioma: a systematic review. Lasers Surg Med. 2016;48(3):221–33.PubMedCrossRef
7.
Darrow DH, Greene AK, Mancini AJ. Diagnosis and Management of Infantile Hemangioma: executive summary. Pediatrics. 2015;136(4):786–91.PubMedCrossRef
8.
Léauté-Labrèze C. Dumas de la Roque E, Hubiche T. propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–51.PubMedCrossRef
9.
Price A, Rai S, Mcleod RWJ, Birchall JC, Elhassan HA. Topical propranolol for infantile haemangiomas: a systematic review. J Eur Acad Dermatol Venereol. 2018;32(12):2083–9.PubMedCrossRef
10.
Prey S, Voisard JJ, Delarue A, Lebbe G, Taïeb A, Léauté-Labrèze C, Ezzedine K. Safety of propranolol therapy for severe infantile Hemangioma. JAMA. 2016;315(4):413–5.PubMedCrossRef
11.
Bayart CB, Tamburro JE, Vidimos AT, Wang L, Golden AB. Atenolol versus propranolol for treatment of infantile Hemangiomas during the proliferative phase: a retrospective noninferiority study. Pediatr Dermatol. 2017;34(4):413–21.PubMedCrossRef
12.
Khan M, Boyce A, Prieto-Merino D, Svensson Å, Wedgeworth E, Flohr C. The role of topical Timolol in the treatment of infantile Hemangiomas: a systematic review and meta-analysis. Acta Derm Venereol. 2017;97(10):1167–71.PubMedCrossRef
13.
Ran Y, Chen S, Dai Y, Kang D, Lama J, Ran X, Zhuang K. Successful treatment of oral itraconazole for infantile hemangiomas: a case series. J Dermatol. 2015;42(2):202–6.PubMedCrossRef
14.
Triana P, Dore M, Cerezo VN, Cervantes M, Sánchez AV, Ferrero MM, González MD, Lopez-Gutierrez JC. Sirolimus in the treatment of vascular anomalies. Eur J Pediatr Surg. 2017;27(1):86–90.PubMed
15.
Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Engl J Med. 2012;366(4):384–6.PubMedCrossRef
16.
Horbach SE, Jolink F, van der Horst CM. Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes. Dermatol Ther. 2016;29(6):466–9.PubMedCrossRef
17.
Hatok J, Babusikova E, Matakova T, Mistuna D, Dobrota D, Racay P. In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med. 2009;9(1):1–7.PubMedCrossRef
18.
Bauer JH, Pape B, Zajicek J, Groshong T. Propranolol in human plasma and breast milk. Am J Cardiol. 1979;43(4):860–2.PubMedCrossRef
19.
Tejani A, Alexander S, Ettenger R, Lerner G, Zimmerman J, Kohaut E, Briscoe DM. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant. 2004;8(2):151–60.PubMedCrossRef
20.
Cree IA, Kurbacher CM, Untch M, et al. Correlation of clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs. 1996;7:630–5.PubMedCrossRef
21.
Neubauer H, Stefanova M, Solomayer E, et al. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res. 2008;28:949–55.PubMed
22.
Morgan MM, Johnson BP, Livingston MK, Schuler LA, Alarid ET, Sung KE, Beebe DJ. Personalized in vitro cancer models to predict therapeutic response: challenges and a framework for improvement. Pharmacol Ther. 2016;165:79–92.PubMedPubMedCentralCrossRef
23.
Van Ingen J, Kuijper EJ. Drug susceptibility testing of nontuberculous mycobacteria. Future Microbiol. 2014;9(9):1095–110.PubMedCrossRef
24.
Zhang J, Li H. Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay. Oncol Lett. 2015;9(5):2374–80.PubMedPubMedCentralCrossRef
25.
Smith CJF, Friedlander SF, Guma M, Kavanaugh A, Chambers CD. Infantile Hemangiomas: an updated review on risk factors, pathogenesis, and treatment. Birth Defects Res. 2017;109(11):809–15.PubMedCrossRef
26.
Choi CH, Ryu JY, Cho YJ, Jeon HK, Choi JJ, Ylaya K, Lee YY, Kim TJ, Chung JY, Hewitt SM, Kim BG, Bae DS, Lee JW. The anti-cancer effects of itraconazole in epithelial ovarian cancer. Sci Rep. 2017;7(1):6552.PubMedPubMedCentralCrossRef
27.
Goss JA, Konczyk DJ, Alomari MH, Maclellan RA, Greene AK. Propranolol treatment of vascular anomalies other than infantile Hemangioma. J Craniofac Surg. 2017;28(8):2001–3.PubMedCrossRef
28.
Phillips JD, Zhang H, Wei T, Richter GT. Expression of β-adrenergic receptor subtypes in proliferative, Involuted, and propranolol-responsive infantile Hemangiomas. JAMA Facial Plast Surg. 2017;19(2):102–7.PubMedCrossRef
29.
Rankin H, Zwicker K, Trenor CC 3rd. Caution is recommended prior to sildenafil use in vascular anomalies. Pediatr Blood Cancer. 2015;62(11):2015–7.PubMedCrossRef
Metadata
Title
Application of the adenosine triphosphate sensitivity assay in infantile vascular anomalies
Authors
Li Li
Bin Yang
Li Wei
Bin Zhang
Xiao-feng Han
Zi-gang Xu
Lin Ma
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2020
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-020-1974-9

Other articles of this Issue 1/2020

BMC Pediatrics 1/2020 Go to the issue

Research article

Cholinergic innervation and ganglion cell distribution in Hirschsprung’s disease

Case report

Clinical and Genetic Study on a Chinese Patient with Infantile Onset Epileptic Encephalopathy carrying a PPP3CA Null Variant: a case report

Research article

The risk of acute events among patients with sickle cell disease in relation to early or late initiation of care at a specialist center: evidence from a retrospective cohort study

Research article

Final adult height of children with idiopathic short stature: a multicenter study on GH therapy alone started during peri-puberty

Research article

Does implementation of the PECARN rules for minor head trauma improve patient-centered outcomes in a lower resource emergency department: a retrospective cohort study

Research article

Screening of vitamin D and calcium concentrations in neonates of mothers at high risk of vitamin D deficiency